上海这家龙头企业，冲刺A股IPO！

Core Viewpoint - Shanghai Chaoqun Detection Technology Co., Ltd. has received approval for its IPO guidance registration, aiming to list on the A-share market with China International Capital Corporation as its advisory institution [1][3]. Company Overview - Established in August 2001, Chaoqun Detection is a leading global enterprise in X-ray core components, with extensive experience and technical strength in R&D, production, and innovation [3]. - The company is recognized as a national high-tech enterprise and has been selected as a "little giant" enterprise under the national specialized and innovative program [3]. Market Position and Opportunities - The domestic medical CT equipment market has seen significant growth, with local products capturing about 50% of the market share. However, the CT tube segment still heavily relies on imports, with international companies like GE Healthcare, Philips, and Siemens holding approximately 70% of the market [4]. - The Ministry of Commerce announced an anti-dumping investigation into imported X-ray tubes from the U.S. and India, presenting new market opportunities for Chaoqun Detection [4]. Development History - Chaoqun Detection has a rich history in X-ray technology, tracing back to the first industrial X-ray machine produced in 1959. The company has made significant strides in the medical sector, acquiring Shanghai Medical Equipment No. 9 Factory in 2016 [5]. - The company expanded into the high-end medical CT tube market by acquiring the DUNLEE factory in Chicago, a pioneer in X-ray tube manufacturing [5]. Product Development - In 2019, Chaoqun Detection established a CT tube factory named Coronos, becoming the only domestic company capable of independent, multi-variety, and large-scale production of high-power medical CT tubes [6]. - The company has developed and launched several products, including the AU200C40L and AU240 CT tubes, which have gained over 10% of the domestic replacement tube market share within a year of their launch [6]. Strategic Partnerships - In late 2024, Chaoqun Detection signed a strategic cooperation agreement with China Medical Device Co., Ltd. to promote the localization of CT systems through joint R&D efforts [7]. Financing and Growth Potential - Prior to its IPO, Chaoqun Detection completed three rounds of financing, with the latest round in January 2024 raising nearly 200 million yuan to enhance product development and R&D capabilities [8]. - The market for 8MHU tubes is projected to reach approximately 6 billion yuan by 2025, with a compound annual growth rate of 7%, indicating strong growth potential for the company [9]. Industry Impact - The company's IPO is expected to set a benchmark for domestic high-end medical core components, potentially reducing reliance on imported products and attracting more resources to the sector [10].